The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe

Inflammatory Bowel Disease

Validation of the "German Inflammatory Bowel Disease Activity Index (GIBDI)": An Instrument for Patient-Based Disease Activity Assessment in Crohn's Disease and Ulcerative Colitis

Z Gastroenterol.

Hüppe A, Langbrandtner J, Häuser W, Raspe H, Bokemeyer B

doi: 10.1055/a-0605-4080.

Inflammatory Bowel Disease

Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States

Inflamm Bowel Dis.

Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D

doi: 10.1093/ibd/izz204.

Inflammatory Bowel Disease

Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors

Am J Gastroenterol.

Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, DʼHaens G, Feagan BG, Sandborn WJ, Jairath V, Singh S

doi: 10.14309/ajg.0000000000000596.

Inflammatory Bowel Disease

Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis

J Crohns Colitis.

Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K

doi: 10.1093/ecco-jcc/jjy149.

Inflammatory Bowel Disease

High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease

Inflamm Bowel Dis.

Barnes EL, Long MD, Kappelman MD, Martin CF, Sandler RS

doi: 10.1093/ibd/izy378.

Inflammatory Bowel Disease

A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials

J Crohns Colitis.

Li K, Strauss R, Marano C, Greenbaum LE, Friedman JR, Peyrin-Biroulet L, Brodmerkel C, De Hertogh G

doi: 10.1093/ecco-jcc/jjz022.

RECOMMENDED

Inflammatory Bowel Disease

First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

★ 2 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

Clin Gastroenterol Hepatol.

Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ

doi: 10.1016/j.cgh.2020.01.008.

Inflammatory Bowel Disease

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

N Engl J Med.

Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S, VARSITY Study Group.

doi: 10.1056/NEJMoa1905725.

Inflammatory Bowel Disease

Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis

J Crohns Colitis

Ghosh S, Sanchez Gonzalez Y, Zhou W, Clark R, Xie W, Louis E, Loftus EV Jr, Panes J, Danese S

doi: 10.1093/ecco-jcc/jjab099

Related content

Validation of the "German Inflammatory Bowel Disease Activity Index (GIBDI)": An Instrument for Patient-Based Disease Activity Assessment in Crohn's Disease and Ulcerative Colitis

Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States

Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors

Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis

High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease

A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials

First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis